| BAC |
Report |
EPS |
BEAT |
pred ~$1.15 vs. cons $1.12 |
MEDIUM |
| BAC |
Report |
Net Interest Income (NII, FTE) |
BEAT |
pred ~$16.30B vs. cons $16.1B |
MEDIUM |
| BAC |
Report |
Total Revenue |
BEAT |
pred ~$30.9B vs. cons $30.56B |
MEDIUM |
| BAC |
Guide |
FY2026 NII growth guidance |
UNCHANGED |
guide ~7% vs. cons ~7% (FY2026, prior range 6-8%) |
MEDIUM |
| BAC |
Guide |
Operating leverage target |
UNCHANGED |
guide ~250bps vs. cons ~240bps (FY2026, prior 200-300bps range) |
LOW |
| BAC |
Guide |
CET1 ratio / capital buffer commentary |
UNCHANGED |
guide ~11.2% vs. cons ~11.2% (Q3 2026) |
MEDIUM |
| BAC |
Guide |
Buyback pace |
BETTER |
guide ~$7.5B vs. cons ~$7.0B (Q3 2026 repurchases) |
LOW |
| BAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-0.4% |
— |
MEDIUM |
| BAC |
Return |
5-day cumulative residual |
-0.8% (FADE) |
Stock is near all-time highs with a very high bar already priced in (25% EPS growth, 9%+ NII growth consensus); a modest headline beat with guidance merely reiterated (not raised, unlike Q1) offers little fresh upside catalyst. Management has explicitly flagged that H2 2026 NII comps get tougher as last year's fixed-asset repricing benefit was H2-weighted, so analysts are likely to trim out-quarter NII/EPS growth rates even after an in-line-to-modest Q2 beat, causing an initial pop to fade over the following days as revisions normalize forward estimates. |
LOW |